Inhibikase Therapeutics, Inc. (IKT) Market Cap
Inhibikase Therapeutics, Inc. has a market capitalization of $129.2M.
Financials based on reported quarter end 2025-12-31
Price: $1.82
▲ 0.15 (8.98%)
Market Cap: 129.23M
NASDAQ · time unavailable
CEO: Mark T. Iwicki
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-12-23
Website: https://www.inhibikase.com
Inhibikase Therapeutics, Inc. (IKT) - Company Information
Market Cap: 129.23M · Sector: Healthcare
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Analyst Sentiment
Based on 2 ratings
Analyst 1Y Forecast: $4.00
Average target (based on 2 sources)
Consensus Price Target
Low
$4
Median
$4
High
$4
Average
$4
Potential Upside: 119.8%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"IKT reported revenue of -73,622 and net income of -12,734,651 (EPS: -0.10) for the latest period ending 2025-12-31, indicating continued bottom-line pressure. Net margin is negative given the loss profile. Free cash flow was -7,967,996, with operating cash flow of -7,515,973 and capex of -452,023, suggesting cash generation did not cover reinvestment needs. On the balance sheet, total assets were 181,204,516 versus total liabilities of 8,300,837, leaving equity of 172,903,679. Net debt was -139,220,208, implying net cash (more cash than debt), which supports near-term financial resilience despite operating losses. From a valuation and sentiment perspective, the consensus price target is 4 (high/low both 4), while the stock price is 1.63, and performance has been weak over longer horizons (1-year: -31.80%; YTD: -16.41%) with modest 6-month improvement (+5.16%). With no dividends paid, total shareholder returns rely entirely on price movement; given the negative 1-year performance and persistent losses, shareholder value creation appears challenged. Overall, the setup reflects a balance-sheet strength offset by ongoing profitability and cash-flow weakness."
Revenue Growth
Revenue is reported as -73,622 for the latest period; without prior-period figures, directional growth cannot be confirmed, but the negative figure underscores material underlying pressure or accounting-driven volatility.
Profitability
Net income of -12,734,651 and EPS of -0.10 indicate continued losses, with negative net margins and no evident earnings recovery in the most recent data.
Cash Flow Quality
Operating cash flow was -7,515,973 and free cash flow was -7,967,996, showing cash burn. Dividends were 0 and no buybacks were provided, so shareholder cash return support is absent.
Leverage & Balance Sheet
Total assets of 181,204,516 versus liabilities of 8,300,837 results in strong equity (172,903,679). Net debt of -139,220,208 implies net cash positioning, supporting resilience even during losses.
Shareholder Returns
Dividends are zero and buybacks were not provided. Price performance has been negative over 1-year (-31.80%) and YTD (-16.41%), limiting total return generation despite a modest 6-month rebound (+5.16%).
Analyst Sentiment & Valuation
Consensus price target is 4 versus a current price of 1.63 (upside suggested by analysts), but valuation ratios (P/E, FCF yield, ROE, debt/equity) are not provided and the loss/FCF burn profile reduces confidence in fundamentals-based support.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
So what: the quarter itself was financially manageable (net loss narrowed to $5.0M from $5.8M; R&D fell $1.4M year-over-year; cash $7.9M with runway into December). The real swing factors are clinical timelines—risvodetinib topline in November and a planned 12-month OLE launch in the coming couple of months—and regulatory milestones (IND filed Aug 9 for IkT-001Pro PAH; FDA indicates 505(b)(2) path). However, the Q&A reveals execution and funding friction. For risvo, an OLE initiation delay led to some patients potentially transitioning to symptomatic therapy (company says it’s a small group, but it’s happening). For PAH, management provided concrete operational hurdles: a rapidly fatal population requiring extension enrollment for every patient (9-12 months to gear up) and a hard gating factor of capital (current cash “not adequate” for trial scale). Analysts pressed for trial size, timelines, and what could derail starts; management answered with numbers, but also with reliance on future funding and operational complexity—tempering the optimistic tone of the prepared remarks.
Growth Catalysts
- Phase 2 201 risvodetinib (risvo) enrollment completed; topline data expected in November
- Potential FDA alignment for IkT-001Pro in pulmonary arterial hypertension (PAH); IND filed on Aug 9 with plans for a de-risking Phase 2b
- Launch of 12-month open-label extension (OLE) for risvo targeted for the coming couple of months as US sites/32-site infrastructure are completed
- In December: expected FDA meeting to discuss Phase 3 plans for risvo
Business Development
- US FDA engagement re: IkT-001Pro in PAH; FDA confirmed 001Pro viewed as a new molecular entity and approval path appears to be 505(b)(2)
- NINDS grant applications under review for risvo-related antibody diagnostic/clinical biomarker tools and alternative financing for MSA (Multiple System Atrophy) via neuroscience clinical development grant mechanism
Financial Highlights
- Net loss: $5.0M (=$0.66/share) vs $5.8M (=$0.94/share) in Q2 2023
- R&D expense: $3.1M vs $4.5M prior-year period (decrease of $1.4M from IkT-001Pro; completion of 3-part dose-finding dose equivalent study in 2023; additional -$0.1M other R&D)
- SG&A: $2.0M vs $1.8M prior-year period (increase driven by +$0.4M legal/consulting; partially offset by -$0.1M D&O insurance and -$0.1M other SG&A)
- Cash position: $7.9M cash, cash equivalents and marketable securities as of June 30, 2024; runway expected into December 2024
- Raised capital in May: $4.0M aggregate gross proceeds from registered direct offering + concurrent private placement
Capital Funding
- May financing: $4.0M aggregate gross proceeds (registered direct + concurrent private placement)
- Cash runway: sufficient to fund operations into December 2024
- Explicit hurdle: PAH trial funding not covered by current cash (~$8M stated in Q&A), cited as 'not adequate' for the scale of trials
Strategy & Ops
- Risvo OLE: preparative work completed (regulatory + ethics steps); OLE launch delayed by 'financial constraints' and now expected in 'coming couple of months' with full force across 32 US sites
- Phase 3 recruitment approach: aim to enroll ~300-400 total across two global Phase 3 trials; dosed up to 12 months; monotherapy design to avoid confounding symptomatic therapies
- PAH prodrug manufacturing/process ramp: scaled manufacturing and process development for 001Pro to support late-stage clinical + NDA batch requirements; development of new dosage forms to differentiate 001Pro tablets from generic imatinib in line with FDA feedback
Market Outlook
- Risvo Phase 3: FDA meeting anticipated by year-end to discuss Phase 3 plans; topline risvo data in November expected to determine Phase 3 direction/effect size
- Phase 2b PAH: de-risking study design roughly 100 patients, two doses, placebo-controlled; planned 12-week safety review at half enrollment completion and futility analysis at half patients completing 24 weeks
Risks & Headwinds
- Risvo OLE lag/patient drop-in: transition from 12-week blinded period to OLE may create a window where some patients may opt for symptomatic treatment; company stated this is already occurring (89 completed currently; 31 still on medication; oldest exits trial in late September) but 'so far, it's been a small group'
- Risvo development risk: in Parkinson’s disease, management notes prior disease-modifying attempts have failed 'with virtually no exceptions' (with one possible exception referenced: GLP-1 related molecule where patients were on symptomatic therapy)
- PAH execution risk: patient population is 'rapidly fatal' requiring infrastructure to ensure every patient can roll into an extension study; company estimates 9-12 months to gear up whole trial execution
- PAH funding constraint: explicit gating factor cited as capital—current cash (~$8M) 'not adequate to do trials of this kind', requiring additional funding to execute
- PAH site/infrastructure complexity: need to enroll every patient into extension study for as long as it takes to get to approval, creating high operational/infrastructure demands
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the IKT Q2 2024 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.